![](/img/cover-not-exists.png)
Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., Knowles, H., Rivera, V. M., Kreisberg, J., Bedrosian, C. L., ToVolume:
26
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2007.12.0345
Date:
January, 2008
File:
PDF, 400 KB
english, 2008